Short description
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
Description
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
White Plains, New York, United States, North America
Founded on
January 1, 2017
Exited on
June 25, 2021
Went public on
June 25, 2021
Stock symbol
ACXP
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Founders
David Luci, Robert G. Shawah